Skip to main content
. 2021 Oct 14;2(4):100174. doi: 10.1016/j.xinn.2021.100174

Figure 6.

Figure 6

Engineering magnetosomes for high-performance cancer vaccination

(A) Fabrication process of A/M/C-MNC.

(B) Schematic illustration of A/M/C-MNC-mediated cellular immune responses to elicit CTLs and memory T cells (TM cells) for cancer immunotherapy.

(C) Bioluminescence images of hematogenous metastasis in lungs after intravenous inoculation of luciferase-expressing 4T1 (Luc-4T1) cells with different pretreatments: (I) PBS; (II) MF; (III) M-MNC; (IV) M/C-MNC; (V) A/M/C-MNC; (VI) A/M/C-MNC with magnetic retention; (VII) A/M/C-MNC with magnetic retention and anti-PD-1.

(D) MFI statistics of lung metastasis in (C). (mean ± SD, n = 6, ∗∗∗P < 0.01)

(E) Survival rate of mice in (C).

Reproduced with permission from Li et al.131 Copyright 2019, American Chemical Society.